{"id":"rasagiline-mesylate-with-levodopa","safety":{"commonSideEffects":[{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL1201142","moleculeType":"Small molecule","molecularWeight":"267.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rasagiline selectively inhibits MAO-B, the enzyme responsible for breaking down dopamine, thereby prolonging dopamine availability in the striatum. Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine by aromatic amino acid decarboxylase. Together, this combination maximizes dopamine levels to alleviate motor symptoms of Parkinson's disease.","oneSentence":"Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while levodopa is converted to dopamine to replace depleted neurotransmitter in Parkinson's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:01.928Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease (motor symptom management)"}]},"trialDetails":[{"nctId":"NCT02384512","phase":"","title":"Azilect® In Wearing-Off (AIWO)","status":"COMPLETED","sponsor":"Teva Pharma GmbH","startDate":"2014-01","conditions":"Parkinson's Disease","enrollment":261},{"nctId":"NCT01479530","phase":"PHASE3","title":"Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2011-12","conditions":"Parkinson's Disease","enrollment":321},{"nctId":"NCT02696512","phase":"PHASE1, PHASE2","title":"A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness","status":"UNKNOWN","sponsor":"International Brain Research Foundation","startDate":"2016-03","conditions":"Brain Injury","enrollment":30},{"nctId":"NCT01556165","phase":"PHASE3","title":"Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2012-04","conditions":"Parkinson's Disease","enrollment":130},{"nctId":"NCT01268891","phase":"PHASE3","title":"Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2011-01","conditions":"Parkinson's Disease","enrollment":132},{"nctId":"NCT01736891","phase":"PHASE3","title":"Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations","status":"COMPLETED","sponsor":"Chongqing Fortune Pharmaceutical Co., Ltd.","startDate":"2011-11","conditions":"Parkinson´s Disease","enrollment":268},{"nctId":"NCT00203060","phase":"PHASE3","title":"Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"1997-07","conditions":"Parkinson's Disease","enrollment":404},{"nctId":"NCT00399477","phase":"PHASE4","title":"A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":200},{"nctId":"NCT00203034","phase":"PHASE3","title":"Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2000-05","conditions":"Parkinson's Disease","enrollment":472},{"nctId":"NCT00203177","phase":"PHASE3","title":"Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2001-10","conditions":"Parkinson's Disease","enrollment":254},{"nctId":"NCT00203164","phase":"PHASE3","title":"Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2002-05","conditions":"Parkinson's Disease","enrollment":254}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rasagiline mesylate with Levodopa","genericName":"Rasagiline mesylate with Levodopa","companyName":"Teva Neuroscience, Inc.","companyId":"teva-neuroscience-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while levodopa is converted to dopamine to replace depleted neurotransmitter in Parkinson's disease. Used for Parkinson's disease (motor symptom management).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}